BACKGROUND: Chronic hepatitis C virus (HCV) infection is an important public health issue owing to its worldwide prevalence and its profound effects on patients' well-being and function. We developed a new patient self-report tool, the HCV patient-reported outcomes (HCV-PRO) instrument, to assess patients' function and well-being reflecting both HCV disease and treatment burdens. METHODS: Items were developed through a qualitative phase including scientific literature review, expert appraisal, and semi-structured patient interviews. The item pool was initially psychometrically tested in 60 adult HCV patients, 18 years of age or older at a university hepatology clinic. A final psychometric test was conducted in 241 members of the online Harris International Panel to examine scale reliability, confirm factor structure, and assess convergent and discriminant validity. RESULTS: A single-factor 16-item HCV-PRO instrument demonstrated good model fit. The HCV-PRO items and total score (range 0-100) showed excellent item response (few floor and ceiling effects) and reliability (alpha > 0.90). Convergent validity was established from moderate to high (r > 0.50) correlation with symptom burden, life satisfaction (ladder of life), and SF-36v2 scales scores. Mean HCV-PRO scores differentiated between currently treated patients, those previously treated, and patients never treated (p < 0.01), suggesting strong known-groups validity. CONCLUSIONS: The results provide initial evidence that the HCV-PRO can yield reliable and valid measurement of the effects of HCV and its treatment on the well-being and function of HCV-infected patients.
BACKGROUND:Chronic hepatitis C virus (HCV) infection is an important public health issue owing to its worldwide prevalence and its profound effects on patients' well-being and function. We developed a new patient self-report tool, the HCVpatient-reported outcomes (HCV-PRO) instrument, to assess patients' function and well-being reflecting both HCV disease and treatment burdens. METHODS: Items were developed through a qualitative phase including scientific literature review, expert appraisal, and semi-structured patient interviews. The item pool was initially psychometrically tested in 60 adult HCVpatients, 18 years of age or older at a university hepatology clinic. A final psychometric test was conducted in 241 members of the online Harris International Panel to examine scale reliability, confirm factor structure, and assess convergent and discriminant validity. RESULTS: A single-factor 16-item HCV-PRO instrument demonstrated good model fit. The HCV-PRO items and total score (range 0-100) showed excellent item response (few floor and ceiling effects) and reliability (alpha > 0.90). Convergent validity was established from moderate to high (r > 0.50) correlation with symptom burden, life satisfaction (ladder of life), and SF-36v2 scales scores. Mean HCV-PRO scores differentiated between currently treated patients, those previously treated, and patients never treated (p < 0.01), suggesting strong known-groups validity. CONCLUSIONS: The results provide initial evidence that the HCV-PRO can yield reliable and valid measurement of the effects of HCV and its treatment on the well-being and function of HCV-infectedpatients.
Authors: I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864
Authors: Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: Andrew Trigg; Eric Chan; Helen Kitchen; Tom Willgoss; Kai Fai Ho; Renee Pierson; Jane Scott Journal: J Health Econ Outcomes Res Date: 2019-02-18
Authors: D M Evon; J Amador; P Stewart; B B Reeve; A S Lok; R K Sterling; A M Di Bisceglie; N Reau; M Serper; S Sarkar; J K Lim; C E Golin; M W Fried Journal: Aliment Pharmacol Ther Date: 2018-01-29 Impact factor: 8.171
Authors: Roger T Anderson; Robert W Baran; Pennifer Erickson; Dennis A Revicki; Birgitta Dietz; Katherine Gooch Journal: Qual Life Res Date: 2013-09-14 Impact factor: 4.147
Authors: Donna M Evon; Souvik Sarkar; Jipcy Amador; Anna S Lok; Richard K Sterling; Paul W Stewart; Bryce B Reeve; Marina Serper; Nancy Reau; K Rajender Reddy; Adrian M Di Bisceglie; David R Nelson; Carol E Golin; Joseph K Lim; Michael W Fried Journal: J Hepatol Date: 2019-05-13 Impact factor: 30.083
Authors: Andrew Richard Armstrong; Susan Elizabeth Herrmann; Olivier Chassany; Christophe Lalanne; Mariliza Henrique Da Silva; Eliana Galano; Patrizia M Carrieri; Vincent Estellon; Philippe Sogni; Martin Duracinsky Journal: BMC Infect Dis Date: 2016-08-23 Impact factor: 3.090
Authors: Donna M Evon; Paul W Stewart; Jipcy Amador; Marina Serper; Anna S Lok; Richard K Sterling; Souvik Sarkar; Carol E Golin; Bryce B Reeve; David R Nelson; Nancy Reau; Joseph K Lim; K Rajender Reddy; Adrian M Di Bisceglie; Michael W Fried Journal: PLoS One Date: 2018-08-01 Impact factor: 3.240
Authors: Mark S Sulkowski; Juhi S Moon; Kenneth E Sherman; Giuseppe Morelli; Jama M Darling; Andrew J Muir; Mandana Khalili; Dawn A Fishbein; Federico Hinestrosa; Mitchell L Shiffman; Adrian Di Bisceglie; K Rajender Reddy; Brian Pearlman; Anna S Lok; Michael W Fried; Paul W Stewart; Joy Peter; Summer Wadsworth; Scott Kixmiller; Anquenette Sloan; Monika Vainorius; Patrick M Horne; Larry Michael; Meichen Dong; Donna M Evon; Jodi B Segal; David R Nelson Journal: Hepatology Date: 2021-08-26 Impact factor: 17.425